Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Original Submission
6 Jul 2020 Submitted Original manuscript
11 Aug 2020 Author responded Author comments - Oscar Arrieta
13 Jul 2020 Reviewed Reviewer Report
19 Jul 2020 Reviewed Reviewer Report
27 Jul 2020 Reviewed Reviewer Report
Resubmission - Version 2
11 Aug 2020 Submitted Manuscript version 2
19 Aug 2020 Author responded Author comments - Oscar Arrieta
12 Aug 2020 Reviewed Reviewer Report
12 Aug 2020 Reviewed Reviewer Report
Resubmission - Version 3
19 Aug 2020 Submitted Manuscript version 3
Publishing
24 Aug 2020 Editorially accepted
1 Sep 2020 Article published 10.1186/s12885-020-07329-8

You can find further information about peer review here.

Back to article page